Merck Shareholders Can See Documents Company Gave to DOJ

Merck & Co. Inc. has already paid nearly $1 billion to the federal government to resolve claims that it misbranded its painkiller Vioxx. To make matters worse, the drug giant has now lost a bid to keep Merck's shareholders from seeing potentially damaging documents that the company turned over to the U.S. Department of Justice.

This article requires premium access

This article requires premium access to The American Lawyer. Please sign in or subscribe to read the full text.